A gynecological preparation from Richter has received marketing authorization in Japan
The partner of Richter Gedeon Nyrt., Fuji Pharma Co., Ltd., received the marketing authorization for the Alyssa combination tablet developed in Japan. The approval means a milestone payment of 10 million euros for Richter’s 100 percent subsidiary, Estetra SRL, Richter announced on Tuesday on the website of the Budapest Stock Exchange.
The Alyssa combined tablet is a preparation for the treatment of dysmenorrhea – painful, crampy menstruation – which contains, among other things, a natural estrogen (estetrol), which has marketing rights in Japan and Southeast Asia.
In the Association of Nations (ASEAN) region, Fuji acquired it from Estetra SRL.
Fuji Alyssa is preparing to launch the combination pill under the trade name to provide a new treatment option for dysmenorrhoea patients.
Related news
According to a survey, young people value sustainability and environmental expectations the most
Young people primarily expect sustainability and the protection of environmental…
Read more >Related news
NGM: the food industry and pharmaceutical production are also performing well
Based on Friday’s data from the Central Statistical Office (KSH),…
Read more >
FAO: The time has come to make the right to a healthy, nutritious and affordable diet a reality
The theme of this year’s World Food Day is “The…
Read more >
The international listing of sugar led to an increase in the price of the main food commodities
According to the Friday report of the Food and Agriculture…
Read more >
